Description
What is the Sublingual Oral Spray?
This is a sublingual spray formulation of Melanotan II (MT-II) a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors to stimulate melanogenesis. The sublingual delivery route administers MT-II to the mucosa beneath the tongue, where the dense sublingual vasculature allows for systemic peptide absorption without the hepatic first-pass metabolism that limits oral bioavailability in most peptide formulations.
Sublingual peptide delivery is an area of active pharmaceutical research. MT-II’s receptor potency and documented mucosal activity make it a useful model compound for comparative absorption studies across non-injectable delivery routes. This formulation contains 20mg MT-II in 10ml.
What Researchers Are Exploring
Sublingual Peptide Bioavailability
The sublingual mucosa provides direct access to the systemic circulation via the lingual veins, offering a faster and more direct absorption pathway than gastrointestinal delivery. Research has explored the pharmacokinetic profiles of peptides administered sublingually including absorption rate, peak plasma concentration, and variability relative to injectable and nasal administration routes.
Melanogenesis & Pigmentation
MT-II’s primary documented effect involves MC1R stimulation on melanocytes, upregulating tyrosinase activity and driving melanin synthesis. The pigmentation research profile established for injectable MT-II provides a reference baseline against which sublingual delivery outcomes can be compared in research settings.
Melanocortin Receptor Activation
As a non-selective melanocortin agonist, MT-II engages MC1R, MC3R, MC4R, and MC5R. Published research continues to explore the downstream effects of each receptor subtype across metabolic, pigmentary, and neurological pathways — with sublingual delivery providing an additional route for studying systemic receptor activation.
Non-Invasive Peptide Administration Research
The development of viable non-injectable delivery formats for peptide compounds is a significant area of pharmaceutical and research interest. MT-II’s documented mucosal stability and receptor potency make it a useful model compound in sublingual delivery studies — particularly for comparing systemic exposure achieved via mucosal routes against injectable reference data.
Worth Noting
The sublingual format is suited to research protocols specifically comparing oral and injectable delivery routes, or where non-invasive administration is a study design requirement. Formulation contains 20mg MT-II in 10ml. As with all non-injectable MT-II formats, bioavailability is expected to be lower than subcutaneous injection this difference in systemic exposure is itself of research interest when comparing mucosal and injectable delivery mechanics.
For research use only. Not approved by the TGA or FDA.
